PCI Synthesis Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • PCI Synthesis's estimated annual revenue is currently $1.2M per year.(i)
  • PCI Synthesis's estimated revenue per employee is $201,000

Employee Data

  • PCI Synthesis has 6 Employees.(i)
  • PCI Synthesis grew their employee count by 0% last year.

PCI Synthesis's People

NameTitleEmail/Phone
1
VP Research & DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is PCI Synthesis?

PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products. PCI Synthesis offers a turnkey solution for all the steps needed to develop a final API, including process research, process development, analytical development, process validation, regulatory support, and FDA filing. PCI Synthesis operates two FDA inspected cGMP sites in the greater Boston area. The company has its headquarters and commercial manufacturing facilities located in Newburyport, MA while its small scale manufacturing and R&D facility is located in Devens, MA. PCI Synthesis has the proven ability to navigate the regulatory process with it's cGMP manufacturing status and DMF submissions. The company is harmonized to the ICH guidelines and is ICH Q7A compliant. The company has undergone both general site and pre-approval inspections from the FDA in 2002, 2003, 2004, 2005, and 2006 as well as numerous customer audits.

keywords:N/A

N/A

Total Funding

6

Number of Employees

$1.2M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M60%N/A
#2
$0.5M7-12%N/A
#3
$0.7M913%N/A
#4
$1.4M90%N/A
#5
$3.3M13-24%N/A